SweetValueLab
Write for us

Universal Health Services, Inc. — Wall Street Analyst Estimates & Price Targets

UHS
NYSEHealthcareMedical - Care FacilitiesCIK 0000352915uhs.comAbout UHS
Last close · Oct 16, 2026185.10−2.26 (−1.21%)
Market cap$10.9B

7 firms' latest targets, last 90 days: median $189.00 ($166.00–$290.00), 2% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$150$200$250$300NovJan 2026MarMayJulSep2025-10-28 · Barclays: $2632025-10-28 · Mizuho Securities: $2422025-10-29 · UBS: $3022025-10-29 · Guggenheim: $2532025-10-29 · Morgan Stanley: $2332025-10-30 · UBS: $2312025-10-30 · RBC Capital: $2312025-11-03 · Raymond James: $2702025-12-02 · Guggenheim: $2742026-01-07 · UBS: $2452026-01-07 · Wells Fargo: $2352026-01-22 · Barclays: $2622026-04-28 · Barclays: $2382026-04-29 · Cantor Fitzgerald: $1942026-04-29 · RBC Capital: $1902026-04-29 · Guggenheim: $2112026-04-29 · Baird: $2042026-04-30 · UBS: $3102026-06-01 · Wells Fargo: $1652026-07-08 · Barclays: $1792026-07-13 · Wells Fargo: $1662026-07-20 · Guggenheim: $1952026-07-28 · Barclays: $1682026-07-29 · UBS: $2902026-07-29 · Guggenheim: $1892026-07-29 · Baird: $1662026-07-29 · Morgan Stanley: $1912026-07-30 · Goldman Sachs: $1902026-08-03 · RBC Capital: $183
$150$200$250$300NovFebMayAug

Each firm's latest target

last 90 days · 7 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-08-03RBC Capital$183.00$190.00▼ 4%+7%-1%
2026-07-30Goldman Sachs$190.00——+13%+3%
2026-07-29UBS$290.00$310.00▼ 6%+74%+57%
2026-07-29Guggenheim$189.00$195.00▼ 3%+14%+2%
2026-07-29Baird$166.00$204.00▼ 19%+0%-10%
2026-07-29Morgan Stanley$191.00$233.00▼ 18%+15%+3%
2026-07-28Barclays$168.00$179.00▼ 6%+5%-9%

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2022reported$13.4B+6%$9.14-23%est. $13.4B+0%est. $9.874
2023reported$14.3B+7%$10.23+12%est. $14.2B+0%est. $10.2810
2024reported$15.8B+11%$16.82+64%est. $15.7B+1%est. $15.9211
2025reported$17.4B+10%$23.10+37%est. $17.4B+0%est. $21.7412
2026$18.6B+7%$22.56+4%$18.5B–$18.9B$22.10–$23.1814
2027$19.5B+5%$23.93+6%$19.2B–$20.0B$22.11–$25.8114
2028$20.4B+5%$26.22+10%$19.3B–$21.1B$24.03–$28.0014
2029$21.2B+4%$26.15+0%$20.7B–$21.7B$25.33–$26.998
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.